Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease
about
Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingPhosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egressNovel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
P2860
Q28362995-D86D51A4-933E-43EF-8E80-1DE3E12CC507Q35103227-12AE2240-563D-4496-A83E-2D41AC6DE021Q36069767-D78F9B6C-564D-429B-B6E6-F8B2E1D32A05Q37624896-C864AF89-E8F3-46B4-A297-0F37D07DB2C1Q37734377-F1A87A17-1EF3-4FE1-83A4-ABFA5B15813BQ37734561-37E507E8-CAD2-44C2-8F66-EE806ACB7CE3Q39474100-BEAC865A-70BC-442C-A7AC-4EEC778341F8Q39652845-30E8FAF1-896A-4193-B145-9340E74EB32CQ39682303-4E463659-E8E2-412A-B79F-560D1DACF9B6Q39699217-AB637123-685D-4C8E-9289-35118D46748CQ40289512-3747F5A5-0C07-471F-B763-FE9FA824B9C0
P2860
Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease
description
1999 nî lūn-bûn
@nan
1999 թուականին հրատարակուած գիտական յօդուած
@hyw
1999 թվականին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Development of novel benzimida ...... ent of cytomegalovirus disease
@ast
Development of novel benzimida ...... ent of cytomegalovirus disease
@en
Development of novel benzimida ...... ent of cytomegalovirus disease
@nl
type
label
Development of novel benzimida ...... ent of cytomegalovirus disease
@ast
Development of novel benzimida ...... ent of cytomegalovirus disease
@en
Development of novel benzimida ...... ent of cytomegalovirus disease
@nl
prefLabel
Development of novel benzimida ...... ent of cytomegalovirus disease
@ast
Development of novel benzimida ...... ent of cytomegalovirus disease
@en
Development of novel benzimida ...... ent of cytomegalovirus disease
@nl
P2093
P1476
Development of novel benzimida ...... ent of cytomegalovirus disease
@en
P2093
G Koszalka
L Townsend
M Underwood
P304
P356
10.1007/978-1-4615-4743-3_12
P407
P577
1999-01-01T00:00:00Z